Experience of using metaprebiotics in the treatment of certain functional gastrointestinal disorders

Introduction. Functional gastrointestinal disorders (FGID) occupy one of the leading positions among intestinal pathologies. At present, scientific data indicate the lack of efficiency of existing methods of FGID treatment and the need for further research. This study is devoted to the assessment of the impact of STIM Lax and STIM treatment on clinical manifestations in patients with FC and FD.Aim of the study. Evaluation of the effectiveness of biologically active additives (BAA) STIM and STIM Laks in 39 patients with functional gastrointestinal disorders. Objectives of the study: to evaluate the effect of the drug on clinical symptoms according to an individual diary and using specialized questionnaires with a score of symptoms before and after treatment.Materials of the research. 39 patients divided into two groups were admitted to the research. Of these, 20 patients were with FC (4 men and 16 women; mean age – 40.3 ± 8.9 years). Monotherapy with STIM Laks was conducted (1 tablet 3 times a day for 30 days), and 19 FD patients (10 men and 9 women; mean age – 36.9 ± 14.1 years). Before and after the course of treatment a carbolene sample was conducted, stool form and frequency, intensity of flatulence, purring, transfusion, abdominal pain were clinically evaluated.Results. Therapy of FС and FD with STIM and STIM Laks effectively reduces the frequency and intensity of clinical symptoms, normalizes the transit time of the carbolene sample, the frequency of stool. Increase of flatulence was observed in 7 (17.9%) patients, its resolution within 1–3 days led to a decrease in the dose of the drug, without affecting the end result.Conclusions. This study indicates a high efficacy and good tolerability of treatment with STIM Laks and STIM in patients with FGID